A Study of Pembrolizumab (MK-3475) Plus V940 in Participants With Bladder Cancer Post-Radical Resection (V940-005)

Inclusion Criteria:

Has muscle-invasive urothelial carcinoma (MIUC)
Has dominant histology of UC
Has high-risk pathologic disease after radical resection
Must provide formalin-fixed paraffin-embedded (FFPE) tumor tissue sample for next generation sequencing (NGS)
Must provide blood samples per protocol, to enable V940 production, and circulating tumor Deoxyribonucleic acid (ctDNA) testing
Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 assessed within 7 days before randomization

Exclusion Criteria:

Has received prior systemic anticancer therapy
Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention
Has known additional malignancy that is progressing or has required active treatment <3 years prior to study randomization
Has severe hypersensitivity to either V940 or pembrolizumab and/or any of their excipients
Has current pneumonitis/interstitial lung disease
Has active infection requiring systemic therapy
Has active hepatitis B and hepatitis C virus infection